Journal of Pharmacological Reports
Open Access

The Role of Pharmacodynamics in Drug Discovery and Development

Arden Jackson^{* *}Correspondence: Arden Jackson, Department of Pharmacy, University of Utah, Salt Lake City, USA, Email:

Author info »

About the Study

Pharmacodynamics refers to the study of the interactions between drugs and the physiological processes of the body. In other words, it is the study of what a drug does to the body and how the body responds to it. Pharmacodynamics is a crucial aspect of pharmacology, the study of drugs and their effects on the body. Understanding pharmacodynamics is essential for the development of safe and effective drugs.

Pharmacodynamics involves several key concepts, including drug potency, efficacy, affinity, and intrinsic activity. These concepts are important in understanding how drugs interact with the body and how they produce their effects.

Drug potency refers to the concentration of a drug required to produce a specific effect. A more potent drug requires a lower concentration to produce the same effect as a less potent drug. For example, morphine is more potent than codeine because it requires a lower concentration to produce the same painrelieving effect.

Efficacy refers to the maximum effect that a drug can produce, regardless of the dose [1]. A drug with high efficacy produces a significant effect at a lower dose, while a drug with low efficacy requires a higher dose to produce the same effect. For example, aspirin has high efficacy as a pain reliever because even a low dose can produce significant pain relief [2].

Affinity refers to the strength of the binding between a drug and its target receptor. A drug with high affinity binds tightly to its target receptor, while a drug with low affinity binds weakly. For example, benzodiazepines have a high affinity for the Gamma- Aminobutyric Acid (GABA) receptor [3], which is why they are effective as anxiolytics and hypnotics.

Intrinsic activity refers to the ability of a drug to activate its target receptor once it has bound to it. A drug with high intrinsic activity produces a significant effect even at a low dose, while a drug with low intrinsic activity produces a weaker effect. For example, morphine has high intrinsic activity at the mu-opioid receptor [4,5], which is why it is effective as a pain reliever.

Pharmacodynamics also involves understanding the mechanism of action of drugs. The mechanism of action refers to how a drug produces its effect at the molecular level [6]. For example, betablockers work by blocking the beta-adrenergic receptors in the heart, which reduces heart rate and blood pressure.

Pharmacodynamics also involves understanding the doseresponse relationship of drugs. The dose-response relationship refers to the relationship between the dose of a drug and the magnitude of its effect [7,8]. A dose-response curve is used to graphically represent this relationship. The dose-response curve typically has four phases: the placebo phase, the linear phase, the plateau phase, and the toxic phase.

The placebo phase is the initial part of the curve where the effect is due to the placebo effect rather than the drug [9]. The linear phase is where the effect increases proportionally with the dose of the drug. The plateau phase is where the effect reaches its maximum, and further increases in the dose do not produce a greater effect [10]. The toxic phase is where further increases in the dose produce harmful effects rather than beneficial effects.

References

1. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol.2016;12(5):259-268.

   [Crossref] [Google scholar] [PubMed]

2. Valade S, Azoulay E, Galicier L, Boutboul D, Zafrani L, Stepanian A,et al. Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis. Medicine. 2015;94(40).

   [Crossref][Google scholar] [PubMed]

3. De la Calle C, López-Medrano F, Pablos JL, Lora-Tamayo J, Maestro-de la Calle G, Sánchez-Fernández M, et al. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study. Int J Infect Dis. 2021;105:319-325.

   [Crossref] [Google scholar] [PubMed]

4. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325-331.

   [Crossref] [Google scholar]

5. England JT, Abdulla A, Biggs CM, Lee AY, Hay KA, Hoiland RL, et al. Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes. Blood Rev. 2021;45:100707.  

   [Crossref] [Google scholar] [PubMed]

6. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med.2021;9(3):251-259.

   [Crossref] [Google scholar]

7. Chu VC, McElroy LJ, Chu V, Bauman BE, Whittaker GR. The avian coronavirus infectious bronchitis virus undergoes direct low-pH-dependent fusion activation during entry into host cells.      J Virol.2006;80(7):3180-3188.

   [Crossref] [Google scholar]

8. Salgotra R, Gandomi M, Gandomi AH. Time series analysis and forecast of the COVID-19 pandemic in India using genetic programming. Chaos Solitons Fractals. 2020; 138:109945.

   [Crossref] [Google scholar]

9. Borneman AR, Gianoulis TA, Zhang ZD, Yu H, Rozowsky J, Seringhaus MR, et al. Divergence of transcription  factor  binding sites across  related  yeast species. Sci. 2007;317(5839):815-819.

   [Crossref] [Google scholar] [PubMed]

10. Komaki H, Sakurai K, Hosoyama A, Kimura A, Igarashi Y, Tamura T. Diversity of nonribosomal peptide synthetase and polyketide synthase gene clusters among taxonomically close Streptomyces strains. Sci Rep. 2018;8(1):1.

    [Crossref] [Google scholar] [PubMed]